Cargando…

Reply to ‘Comment on ‘Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study’’

Detalles Bibliográficos
Autores principales:	Triggiani, Luca, Mazzola, Rosario, Magrini, Stefano Maria, Alongi, Filippo, Buglione, Michela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2018
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808026/ https://www.ncbi.nlm.nih.gov/pubmed/29149106 http://dx.doi.org/10.1038/bjc.2017.406

Ejemplares similares

Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study
por: Triggiani, Luca, et al.
Publicado: (2017)

Comment on ‘Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study’
por: Bravo, Isabel
Publicado: (2018)

Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review
por: Yaney, Alexander, et al.
Publicado: (2022)

Stereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancer()
por: Levy, Antonin, et al.
Publicado: (2023)

In reply to Simcock et al.
por: Magrini, Stefano Maria, et al.
Publicado: (2020)

Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer
por: Kissel, Manon, et al.
Publicado: (2019)

Stereotactic Body Radiation Therapy (SBRT) for Oligorecurrent/Oligoprogressive Mediastinal and Hilar Lymph Node Metastasis: A Systematic Review
por: Cozzi, Salvatore, et al.
Publicado: (2022)

MR-Guided Hypofractionated Radiotherapy: Current Emerging Data and Promising Perspectives for Localized Prostate Cancer
por: Cuccia, Francesco, et al.
Publicado: (2021)

Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance
por: Triggiani, Luca, et al.
Publicado: (2021)

Radiotherapy in nodal oligorecurrent prostate cancer
por: Pinkawa, Michael, et al.
Publicado: (2021)

Stereotactic robotic body radiotherapy for patients with oligorecurrent pulmonary metastases
por: Berkovic, Patrick, et al.
Publicado: (2020)

Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer
por: Weykamp, Fabian, et al.
Publicado: (2020)

Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR)
por: Alomran, Reem, et al.
Publicado: (2021)

Stereotactic body radiotherapy to defer systemic therapy in patients with oligorecurrent disease
por: Willmann, Jonas, et al.
Publicado: (2022)

Role of Radiosurgery/Stereotactic Radiotherapy in Oligometastatic Disease: Brain Oligometastases
por: Mazzola, Rosario, et al.
Publicado: (2019)

Editorial: Stereotactic body radiotherapy for prostate cancer
por: Kishan, Amar U., et al.
Publicado: (2022)

Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients
por: König, Laila, et al.
Publicado: (2020)

Oligorecurrent Prostate Cancer and Stereotactic Body Radiotherapy: Where Are We Now? A Systematic Review and Meta-analysis of Prospective Studies
por: Marvaso, Giulia, et al.
Publicado: (2021)

Effectiveness of Stereotactic Ablative Radiotherapy for Systemic Therapy Respondents with Inoperable Pulmonary Oligometastases and Oligoprogression
por: Ho, Chin-Beng, et al.
Publicado: (2023)

Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer
por: Stefan A. Koerber, et al.
Publicado: (2020)

Predictive factors for response to salvage stereotactic body radiotherapy in oligorecurrent prostate cancer limited to lymph nodes: a single institution experience
por: Oehler, Christoph, et al.
Publicado: (2019)

Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma
por: Schoenhals, Jonathan E., et al.
Publicado: (2021)

Outcomes of Stereotactic Body Radiotherapy for Metastatic Colorectal Cancer With Oligometastases, Oligoprogression, or Local Control of Dominant Tumors
por: Ji, Xiaoqin, et al.
Publicado: (2021)

Stereotactic radiation therapy for oligometastases or oligorecurrence within mediastinal lymph nodes
por: Wang, Huan-Huan, et al.
Publicado: (2016)

Impact of stereotactic body radiotherapy vs palliative radiotherapy on oncologic outcomes of patients with metastatic kidney cancer concomitantly treated with immune checkpoint inhibitors: a preliminary, multicentre experience
por: Francolini, Giulio, et al.
Publicado: (2022)

Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer
por: Wang, Zhen, et al.
Publicado: (2021)

Reply to Ghaffari et al. “In regard to Cuccia et al.: impact of hydrogel peri-rectal spacer insertion on prostate gland intra-fraction motion during 1.5 T MR-guided stereotactic body radiotherapy.”
por: Cuccia, Francesco, et al.
Publicado: (2020)

Node Oligorecurrence in Prostate Cancer: A Challenge
por: Zapatero, Almudena, et al.
Publicado: (2023)

Impact of hydrogel peri-rectal spacer insertion on prostate gland intra-fraction motion during 1.5 T MR-guided stereotactic body radiotherapy
por: Cuccia, Francesco, et al.
Publicado: (2020)

Retreatment of recurrent adult medulloblastoma with radiotherapy: a case report and review of the literature
por: Buglione, Michela, et al.
Publicado: (2013)

Elective nodal radiotherapy with a gapless radiation field junction for oligorecurrent prostate cancer after previous radiotherapy
por: Li, Minglun, et al.
Publicado: (2022)

Prognostic Factors and Optimal Response Interval for Stereotactic Body Radiotherapy in Patients With Lung Oligometastases or Oligoprogression From Colorectal Cancer
por: Li, Shuai, et al.
Publicado: (2019)

Erratum to combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer
Publicado: (2022)

Letter to the Editor regarding ESTRO-ASTRO guidelines on lung cancer radiotherapy during COVID-19 pandemic
por: Magrini, Stefano Maria, et al.
Publicado: (2020)

Stereotactic body radiation therapy for the treatment of oligoprogression on androgen receptor targeted therapy in castration-resistant prostate cancer
por: Nguyen, Thu-Cuc, et al.
Publicado: (2018)

PSMA-PET/CT-Based Stereotactic Body Radiotherapy (SBRT) in the Treatment of Uncomplicated Non-Spinal Bone Oligometastases from Prostate Cancer
por: Pastorello, Edoardo, et al.
Publicado: (2023)

Impact of Gastrointestinal Side Effects on Patients’ Reported Quality of Life Trajectories after Radiotherapy for Prostate Cancer: Data from the Prospective, Observational Pros-IT CNR Study
por: Noale, Marianna, et al.
Publicado: (2021)

1.5T MR-Guided Daily Adaptive Stereotactic Body Radiotherapy for Prostate Re-Irradiation: A Preliminary Report of Toxicity and Clinical Outcomes
por: Cuccia, Francesco, et al.
Publicado: (2022)

Stereotactic radiotherapy for lung oligometastases
por: Falcinelli, Lorenzo, et al.
Publicado: (2022)

Stereotactic radiotherapy for brain oligometastases
por: Lupattelli, Marco, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2r0ubectdtiljjqsk02mul4o32